Demographics of subjects with successfully obtained HIV-1 <i>pol</i> sequences.

<p>Demographics of subjects with successfully obtained HIV-1 <i>pol</i> sequences.</p

Antiretroviral drug resistance mutations in Tanzanian subjects at first line clinico-immunological ART failure.

<p>A) stratified by treatment duration (n = 38); B) stratified by CD4 cells at failure (n = 36).</p

Genotypic sensitivity scores for all reverse transcriptase and protease inhibitors.

<p>Percentage (%) of patient strains classified as susceptible, intermediate or resistant as per the Rega V.9.1.0 algorithm; first line failure (n = 43) and second line virological failure cases (n = 26) presented with separate paired bars (first line left bar, second line right bar).</p

Success probability of future regimen by the EuResist prediction engine.

<p>Prediction is based on drug resistance mutation profile and data on previous drug exposure, age, gender and CD4 at failure. Results are presented in ordered of increasing difference between a scenario where all approved NRTIs, NNRTIs and PIs are available versus currently available drugs in Tanzania. A) subjects failing first line therapy; B) subjects failing second line therapy (viral load included in prediction model).</p

Adherence, health-related QoL and patient-reported symptoms at different time points, based on randomization arm.

<p>Adherence, health-related QoL and patient-reported symptoms at different time points, based on randomization arm.</p

Evolution of (a-d) blood lipids and (e) renal function as by estimated GFR (CKD-EPI) over the 48 study weeks by randomization arm.

<p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p

Proportion of individuals with virological failure over the complete follow-up available until the time of study interruption in the intention to treat population.

<p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p

Proportion of individuals without treatment failure over the 48 study weeks by randomization arm in the (a) per protocol population and (b) intention to treat population.

<p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p

Baseline patients characteristics of the per-protocol population.

<p>Baseline patients characteristics of the per-protocol population.</p

GUSTA flow diagram.

<p>GUSTA flow diagram.</p